plerixafor/low-dose tacrolimus (MRG-001) / MedRegen - LARVOL DELTA

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: MedRegen LLC | Recruiting ➔ Completed

Trial completion • Aesthetic Medicine

SUMMIT: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: MedRegen LLC | Initiation date: Jul 2024 ➔ Dec 2024

Trial initiation date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases • CD34

MRG-001 in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: MedRegen LLC | Trial completion date: Dec 2024 ➔ Mar 2026 | Initiation date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Nov 2024 ➔ Jan 2026

Trial completion date • Trial initiation date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: MedRegen LLC | Trial primary completion date: Jul 2024 ➔ Oct 2024

Trial primary completion date • Aesthetic Medicine

MRG-001 in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: MedRegen LLC

New P2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

MRG-001 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: MedRegen LLC

New P2 trial • Hepatitis C • Hepatology • Inflammation

SUMMIT: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: MedRegen LLC

New P2 trial • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases • CD34

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: MedRegen LLC | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2023 ➔ Nov 2023

Enrollment open • Trial initiation date • Aesthetic Medicine

A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects. (PubMed, Cell Rep Med) - P2a | "MRG-001 is safe across all dose ranges. MRG-001 may be a clinically useful therapy for immunoregulation and tissue regeneration (ClinicalTrials.gov: NCT04646603)."

Journal • P1 data • PK/PD data • Transplant Rejection

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: MedRegen LLC

New P2 trial • Aesthetic Medicine • CD133 • CD34 • FOXP3

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (clinicaltrials.gov) - P2a | N=40 | Recruiting | Sponsor: MedRegen LLC | Active, not recruiting ➔ Recruiting | Phase classification: P2 ➔ P2a | N=18 ➔ 40 | Trial completion date: Mar 2022 ➔ Jul 2022 | Trial primary completion date: Dec 2021 ➔ Mar 2022

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (clinicaltrials.gov) - P2; N=18; Active, not recruiting; Sponsor: MedRegen LLC; Recruiting ➔ Active, not recruiting; Phase classification: P2a ➔ P2; Trial completion date: Jun 2021 ➔ Mar 2022; Trial primary completion date: Apr 2021 ➔ Dec 2021

Clinical • Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (clinicaltrials.gov) - P2a; N=18; Recruiting; Sponsor: MedRegen LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (clinicaltrials.gov) - P2a; N=18; Not yet recruiting; Sponsor: MedRegen LLC; Phase classification: P1/2 ➔ P2a; N=12 ➔ 18

Clinical • Enrollment change • Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients (clinicaltrials.gov) - P1/2; N=12; Not yet recruiting; Sponsor: MedRegen LLC

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases